Please select CHADSVASC and HASBLED risk factors, EHRA score and click copy to clipboard to copy and paste in your electronic files.
Chadsvasc risk factors [click on present risk factors]
| RISK FACTORS | SCORE |
|---|---|
| Congestive heart failure | 1 |
| Hypertension | 1 |
| Age ≥ 75 | 2 |
| Age 65-74 | 1 |
| Diabetes mellitus | 1 |
| Stroke/TIA/thrombo-embolism | 2 |
| Vascular disease | 1 |
| Sex Female | 1 |
| Result | 0 |
Results
CHADSVASC clinical risk estimation. Adapted from Lip et al.
| CHA2DS2VASc SCORE | PATIENTS (n=7329) | ADJUSTED STROKE RATE (% year) |
|---|---|---|
| 0 | 1 | 0 |
| 1 | 422 | 1.3 |
| 2 | 1230 | 2.2 |
| 3 | 1730 | 3.2 |
| 4 | 1718 | 4 |
| 5 | 1159 | 6.7 |
| 6 | 679 | 9.8 |
| 7 | 294 | 9.6 |
| 8 | 82 | 6.7 |
| 9 | 14 | 15.2 |
HASBLED clinical characteristic [click on present risk factors]
| CLINICAL CHARACTERISTIC | POINTS AWARDED |
|---|---|
| Hypertension | 1 |
| Abnormal liver function | 1 |
| Abnormal renal function | 1 |
| Stroke | 1 |
| Bleeding | 1 |
| Labile INRs | 1 |
| Elderly (Age >65) | 1 |
| Drugs | 1 |
| Alcohol | 1 |
| Result | 0 |
Results
HASBLED clinical risk estimation. Adapted from Pisters et al.
| HAS BLED SCORE |
NUMBER OF PATIENTS |
NUMBER OF BLEEDING |
BLEEDS PER 100 PATIENT YEARS |
|---|---|---|---|
| 0 | 798 | 9 | 1.13 |
| 1 | 1286 | 13 | 1.02 |
| 2 | 744 | 14 | 1.88 |
| 3 | 187 | 7 | 3.74 |
| 4 | 46 | 4 | 8.70 |
| 5 | 8 | 1 | 12.50 |
| 6 | 2 | --- | --- |
| 7 | --- | --- | --- |
| 8 | --- | --- | --- |
| 9 | --- | --- | --- |
| Total | 798 | 9 | 1.13 |
Classificaton of AF-related symptoms (EHRA score)
| EHRA I | No symptoms |
| EHRA II | Mild symptoms; normal daily activity not affected |
| EHRA III | Severe symptoms; normal daily activity affected |
| EHRA IV | Disabing symptoms; normal daily activity discontinued |
Recommendations
| Haemorrhagic risk | Stroke risk | Clinical setting | Recommendations according to EHRA / ESC / EAPCI 2014 consensus document |
|---|---|---|---|
| Low or moderate (HAS-BLED 0-2) | Moderate (CHA2DS2-VASC = 1 in males) | Stable CAD | At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC |
| High (CHA2DS2-VASC ≥2) | Stable CAD | At least 4 weeks (no longer than 6 months): triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day< Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC | |
| Moderate (CHA2DS2-VASC = 1 in males) | ACS | 6 months: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC | |
| High (CHA2DS2-VASC ≥2) | ACS | 6 months: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC | |
| High (HAS-BLED ≥3) | Moderate (CHA2DS2-VASC = 1 in males) | Stable CAD | Up to 12th month: OAC and clopidogrel 75 mg/day Lifelong: OAC |
| High (CHA2DS2-VASC ≥2) | Stable CAD | 4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/day Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC | |
| Moderate (CHA2DS2-VASC = 1 in males) | ACS | 4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/dayd Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC | |
| High (CHA2DS2-VASC ≥2) | ACS | 4 weeks: triple therapy of OAC + aspirin 75-100 mg/day + clopidogrel 75 mg/dayd Up to 12th month: OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) Lifelong: OAC |
